Advances and challenges in immunotherapy of small cell lung cancer
Hanfei Guo1, Lingyu Li1, Jiuwei Cui1
1Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Abstract:
Small cell lung cancer (SCLC) is a highly lethal disease, characterized by early metastasis and rapid growth, and no effective treatment after relapse. Etoposide-platinum (EP) combination has been the backbone therapy of SCLC over the past 30 years. It is extremely urgent and important to seek new therapies for SCLC. In the past 5 years, immunotherapy, such as immune checkpoint inhibitors programmed cell death protein-1 (PD-1), cytotoxic T lymphocyte associatedprotein-4 (CTLA-4), has made remarkable achievements in the treatment of patients with SCLC, and it has become the first-line option for the treatment of some patients. Some traditional chemotherapeutic drugs or targeted drugs, such as alkylating agent temozolomide and transcription inhibitor lurbinectedin, have been found to have immunomodulatory effects and are expected to become new immunotherapeutic agents. In this study, we aimed to review the efficacy of new treatments for SCLC and discuss the current challenges and application prospect in the treatment of SCLC patients.
Insights
New treatments, including immunotherapy and modified chemotherapy, offer hope for recurrent small cell lung cancer (SCLC). This review examines their efficacy and future potential against this aggressive disease.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Small cell lung cancer (SCLC) is aggressive with poor outcomes post-relapse.
- Etoposide-platinum (EP) chemotherapy has been the standard for decades but lacks efficacy in recurrent disease.
- Novel therapeutic strategies are urgently needed for SCLC patients.
Purpose of the Study:
- To review the efficacy of emerging treatments for SCLC.
- To discuss current challenges and future prospects for SCLC therapy.
- To highlight the role of immunotherapy and novel agents.
Main Methods:
- Literature review of recent clinical studies and trials.
- Analysis of data on immunotherapy agents (PD-1, CTLA-4 inhibitors).
- Evaluation of chemotherapeutic and targeted drugs with immunomodulatory effects (temozolomide, lurbinectedin).
Main Results:
- Immunotherapy, including PD-1 and CTLA-4 inhibitors, has shown promise as a first-line option for some SCLC patients.
- Chemotherapeutic agents like temozolomide and lurbinectedin exhibit immunomodulatory effects, suggesting potential as novel immunotherapies.
- Significant advancements have been made, but challenges remain in optimizing treatment efficacy and overcoming resistance.
Conclusions:
- New treatment modalities, particularly immunotherapy, are transforming SCLC management.
- Repurposed chemotherapeutic agents may offer new avenues for SCLC immunotherapy.
- Further research is essential to address challenges and improve long-term outcomes for SCLC patients.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...